H
Hangzhou Weiyuan Biotechnology
Synthetic biology for chiral compounds and functional materials
About Hangzhou Weiyuan Biotechnology
Hangzhou Weiyuan Biotechnology Co., Ltd. is a synthetic biology company founded in 2023. The company's technical foundation is built on the directed evolution of enzymes, multi-enzyme cascades, and the integration of enzymatic reactions with chemical synthesis. It leverages intelligent enzyme evolution and high-throughput strain screening as its core technology engine.
The founder and CEO, Wu Yan, graduated from Zhejiang University with a major in Bioengineering and has over two decades of experience in biopharmaceutical R&D and industrialization. The co-founder and CTO, Luo Zhibo, holds a PhD in Engineering from Tsinghua University and has a background in synthetic biology and chemical engineering research.
Weiyuan Biotechnology is focused on building a comprehensive enzyme library to produce chiral compounds, natural product extracts, and functional raw materials. The firm provides high-performance biological elements for the biomanufacturing industry, which are applied to the efficient production of chiral compounds, the enzymatic hydrolysis of active natural products, and the construction of cell-free multi-enzyme cascade systems. Its business serves other companies in the biotechnology sector. The company operates on a venture capital-backed, privately held ownership model and has completed Seed and Early Stage VC funding rounds.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Open positions
- None listed
- Dealroom signal
- 20.3/100
- Industry
- Health, Chemicals
- Sub-industry
- BioTechnology
- Sector
- Biotechnology, Synthetic Biology, Biotech and Pharma, precision fermentation, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- B2B
- Links
- Website
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SEED✓Equity / VC | Aug 2025 | $14M | $55M | Roton Capital · Zhejiang Dajing Venture Capital · Dalton Venture · True Stone Capital | ↗ |
| SEED✓Equity / VC | Jun 2024 | $2.8M | $11M | Undisclosed | ↗ |
Growth signals
Latest recorded traffic for Hangzhou Weiyuan Biotechnology is 1.1K monthly website visits, up 103.7% over the last three months.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Hangzhou Weiyuan Biotechnology in the Hangzhou ecosystem
The Hangzhou Weiyuan Biotechnology office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed4 investors entered at this stage
Roton Capital- ZCZhejiang Dajing Venture Capital
- DVDalton Venture
- TCTrue Stone Capital
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Hangzhou Weiyuan Biotechnology on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Hangzhou Weiyuan Biotechnology’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.









